How has been the historical performance of Marksans Pharma?

Answer:Marksans Pharma has shown a consistent growth trajectory in its historical performance, particularly in net sales and profitability over the years.

Breakdown:
From March 2019 to March 2025, Marksans Pharma's net sales increased significantly from 1,000.07 Cr to 2,622.85 Cr, reflecting a strong upward trend. The total operating income followed a similar pattern, rising from 1,000.07 Cr in March 2019 to 2,622.85 Cr in March 2025. The company's total expenditure also grew, from 867.93 Cr in March 2019 to 2,094.20 Cr in March 2025, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) saw a rise from 136.76 Cr in March 2019 to 599.03 Cr in March 2025, showcasing improved operational efficiency. Profit before tax also increased from 104.31 Cr to 503.97 Cr during the same period, while profit after tax rose from 80.44 Cr to 382.62 Cr. The earnings per share (EPS) demonstrated a positive trend, climbing from 1.97 in March 2019 to 8.4 in March 2025. The operating profit margin slightly fluctuated but remained strong, ending at 20.16% in March 2025, while the PAT margin improved to 14.59%. Overall, Marksans Pharma's financial performance indicates robust growth and profitability over the years.